Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

@article{SantosNunes2010CabergolineVB,
  title={Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis},
  author={Vania Santos Nunes and Regina El Dib and C{\'e}sar Luiz Boguszewski and C{\'e}lia Regina Nogueira},
  journal={Pituitary},
  year={2010},
  volume={14},
  pages={259-265}
}
Cabergoline and bromocriptine are the most used drugs in the treatment of hyperprolactinemia, they are able to normalize the prolactin levels, restore gonadal function and promote tumor reduction in the majority of patients. We undertake a systematic review and meta-analysis of randomized controlled trials to compare cabergoline versus bromocriptine in the treatment of patients with idiopathic hyperprolactinemia and prolactinomas. The data sources were: Embase, Pubmed, Lilacs and Cochrane… 
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review
TLDR
Based on analysis, CAB is significantly better than BRC in normalizing PRL levels in patients, especially males, with giant prolactinomas, and both drugs are comparably effective for patients of both genders.
Comparison Between Bromocriptine and Cabergoline Drugs as a Treatment of Hyperprolactinemia Among Sudanese Infertile Amenorrhic Women
This is a retrospective study, conducted at Reproductive Health Care Centre, Khartoum. The study aimed to compare between bromocriptine and cabergoline medications for treatment of hyperprolactinema
Treatment of hyperprolactinemia: a systematic review and meta-analysis
TLDR
Evidence is provided to support the use of dopamine agonists in reducing prolactin levels and persistent hyperprolactinemia, with cabergoline proving more efficacious than bromocriptine.
Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis
TLDR
The superiority of one drug over another could not be determined due to lack of controlled studies, but the proportion of disease control identified in the meta-analysis may support clinical decision.
Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta‐analysis
TLDR
A systematic review and network meta‐analyses were performed to evaluate the efficacy and safety of dopaminergic agonists in the treatment of hyperprolactinemia.
A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas
TLDR
In conclusion, patients with prolactinomas treated with either CBG or BRC showed higher prevalence of trace and mild Tri or Mi regurgitation, but these findings were not clinically significant.
Physiological Study of Some Hormonal Parameters in Infertile Hyperprolactinemic Women in Pre and Post-Treatment with Cabergoline and Bromocriptine
TLDR
Hyperprolactinemia associated with increased and decreased in some hormonal parameters and the dopamine agonist agents are effective in correcting the disturbance in these parameters.
Dopamine agonists in prolactinomas: when to withdraw?
TLDR
A growing amount of evidence suggests that the post-pregnancy/breastfeeding period and menopause are reasonable timings to re-access the need for continuing DAs therapy.
Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus
TLDR
Cabergoline did not improve diabetic control or normalise insulin-like growth factor concentration, or improve patient quality of life.
Current treatment options for hyperprolactinemia
TLDR
Dopamine agonists, usually cabergoline, remain the primary choice for initial treatment of hyperprolactinemia and monotherapy with dopamine agonists is often successful at controlling prolactin levels and tumor size, but adjunctive treatments may be necessary for resistant or aggressive Prolactinomas.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
TLDR
Cabergoline is a new prolactin-lowering drug, more effective and better tolerated with fewer gastrointestinal symptoms than the reference compound, bromocriptine.
Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea
TLDR
Cabergoline has the advantage over bromocriptine in terms of both efficacy and tolerability and therefore it is preferred in the treatment of hyperprolactinemic amenorrhea.
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
TLDR
Cabergoline is more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea and Gastrointestinal symptoms were significantly less frequent, less severe, and shorter-lived in the women treated with cabergoline.
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
TLDR
The high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia is confirmed, in a large-scale retrospective study, leaving few patients with unacceptable side effects or inadequate clinical response.
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
TLDR
After 24 months, PRL normalization and tumor shrinkage after CAB and BRC treatments, respectively, were obtained in 82.1% and 46.4% of macroprolactinomas and in 90% vs. 56.8% of microprolACTinomas.
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
TLDR
It is indicated that cabergoline is a very effective agent for lowering the prolactin levels in hyperprolactinemic patients and that it appears to offer considerable advantage over bromocriptine in terms of efficacy and tolerability.
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
TLDR
The treatment with CAB normalized PRL levels, improving gonadal and sexual function and fertility in males with prolactinoma, earlier than did BRC treatment, providing good tolerability and excellent patient compliance to medical treatment.
[Treatment of hyperprolactinemic amenorrhea with cabergoline].
TLDR
It is concluded that CAB is a useful therapy for adults and adolescents with hyperprolactinemic amenorrhea because of its easy administration and the almost complete absence of side effects.
The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
TLDR
A high efficacy and a very good tolerability of CAB in the treatment of patients with pituitary adenomas is confirmed and such therapy should be considered the first line option in patients with prolactinomas.
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
TLDR
To investigate whether previous treatment with bromocriptine or quinagolide impairs a subsequent response to long-term cabergoline (CAB) treatment, 110 patients with macroprolactinoma were studied.
...
1
2
3
4
...